MARIANI PETER J

SEC source: 0001104659-26-074291 · tm2618022-1_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 638,113

F1 · shares: The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.45, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, of which 32,500 remain unvested as of the date hereof, and which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; (d) 71,500 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting; and

F5 · balance_after: (continued from footnote 4) (e) 216,613 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-075794 · tm2522995-7_4seq1.xml · derivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2035-08-08

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-25-075794 · tm2522995-7_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 538,113

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F5 · balance_after: (continued from footnote 4) (d) 116,613 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-017620 · tm257709-3_4seq1.xml · derivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,625 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · derivative.exercise_price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

SEC source: 0001104659-25-017620 · tm257709-3_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,613

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F3 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F4 · balance_after: (continued from footnote 3) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F5 · balance_after: (continued from footnote 4) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F6 · balance_after: (continued from footnote 5) (d) 116,613 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · derivative · entry 4

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,625

Underlying: Common Stock · 32,625 shares

Expires 2025-04-10

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F8 · derivative.exercise_price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F8 · price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F9 · derivative.expiration_date: The Series B Right Warrants expire 90 calendar days following the Closing Date.

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · derivative · entry 3

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,625

Underlying: Common Stock · 32,625 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F7 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · derivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,625 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005352 · tm254168-6_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 433,988

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 32,625 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $32,625. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F5 · balance_after: (continued from footnote 4) (d) 83,988 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-24-128667 · tm2431157-1_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,363

F1 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F1 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8902 to $1.09. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F2 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F3 · balance_after: (continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F4 · balance_after: (continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F5 · balance_after: (continued from footnote 4) (d) 51,363 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-24-128223 · tm2431024-1_4seq1.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,363

F2 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F2 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.88 to $0.90. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F3 · balance_after: Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date;

F4 · balance_after: (continued from footnote 3) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

F5 · balance_after: (continued from footnote 4) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

F6 · balance_after: (continued from footnote 5) (d) 31,363 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-24-128223 · tm2431024-1_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 361,363

F1 · kind: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

F1 · price: Reflects open market purchases made by the Reporting Person. The price reported in Column 4 is the weighted average price of purchases made in multiple transactions at prices ranging from $0.8289 to $0.92. The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · derivative · entry 5

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2034-08-14

F5 · derivative.exercise_date: The shares underlying these stock options will vest only upon the achievement of certain milestones pursuant to the terms of the Employment Agreement, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · derivative · entry 4

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2034-08-14

F4 · derivative.exercise_date: The shares underlying these stock options vest in accordance with the following schedule: (i) 41,000 upon the six-month anniversary of the date of grant, and (ii) 13,000 on the one-year, two-year and three-year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

F3 · shares: These shares represent RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the reporting person's employment agreement, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

F2 · shares: These shares represent RSUs which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting.

SEC source: 0001104659-24-090596 · tm2421901-4_4seq1.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

F1 · shares: These shares represent restricted stock units ("RSUs") received as a signing bonus that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon the earlier of (i) a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the reporting person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,603

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,573

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,693

SEC source: 0000805928-23-000141 · wk-form4_1697243414.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,103

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000141 · wk-form4_1697243414.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,366

F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · derivative · entry 8

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · derivative · entry 7

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,500

Underlying: Common Stock · 94,500 shares

Expires 2033-03-16

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · derivative · entry 6

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,250

Underlying: Common Stock · 15,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · derivative · entry 5

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · nonDerivative · entry 4

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,657

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,579

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-23-000022 · wf-form4_167935099493651.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,445

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · derivative · entry 9

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,940 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 6

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,945

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 5

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · derivative · entry 8

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,940

Underlying: Common Stock · 20,939 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 4

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,555

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.36 to $9.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · derivative · entry 7

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,879

Underlying: Common Stock · 20,939 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,936

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000009 · wf-form4_167529511485643.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · derivative · entry 9

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,818

Underlying: Common Stock · 20,940 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 6

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,108

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 5

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · derivative · entry 8

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,758

Underlying: Common Stock · 20,939 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 4

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,108

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.61 to $10.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · derivative · entry 7

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,697

Underlying: Common Stock · 20,939 shares

Expires 2023-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,108

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.76 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-23-000007 · wf-form4_167486001353289.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-22-000141 · wf-form4_167236489532222.xml · derivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,625

Underlying: Common Stock · 2,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter.

F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter.

SEC source: 0000805928-22-000141 · wf-form4_167236489532222.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,108

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.